VCG
ITCI

Vantage Consulting Group’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Vantage Consulting Group’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-226,670
Closed -$11.9M – 235
2021
Q4 		$11.9M Hold
226,670
– – 3.19% 4
2021
Q3 		$8.45M Hold
226,670
– – 1.81% 4
2021
Q2 		$9.25M Hold
226,670
– – 1.61% 5
2021
Q1 		$7.69M Hold
226,670
– – 1.54% 5
2020
Q4 		$7.21M Buy
+226,670
New +$5.96M 0.59% 4

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vantage Consulting Group's ITCI Position: Q1 2022 in Review

Vantage Consulting Group sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2022, closing a stake of 226,670 shares — an estimated $11.9M sold.

Vantage Consulting Group first reported a position in ITCI in Q4 2020 and held it in 5 quarters. The position peaked at $11.9M in Q4 2021. 241 funds tracked by Wall St. Rank hold ITCI as of Q1 2022.

  • Vantage Consulting Group reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2022 after selling out during the quarter.
  • Vantage Consulting Group sold 226,670 Intra-Cellular Therapies Inc. shares in Q1 2022, an estimated $11.9M.
  • Vantage Consulting Group first reported a position in Intra-Cellular Therapies Inc. in Q4 2020 and held it in 5 quarters.
  • Vantage Consulting Group's Intra-Cellular Therapies Inc. position peaked at $11.9M in Q4 2021.
  • 241 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2022.

Based on Vantage Consulting Group's 13F filing for Q1 2022, filed 16 May 2022.